ID

16688

Beskrivning

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Study Drug Administration

Länk

https://clinicaltrials.gov/ct2/show/NCT00373425

Nyckelord

Versioner (2)
  1. 2016-07-27 2016-07-27 -
  2. 2016-08-01 2016-08-01 -
Uppladdad den

1 augusti 2016

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425

Engelsk

Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 Formulär  
Study Drug Administration
Beskrivning

Study Drug Administration

Start Date
Beskrivning

Study Drug Administration Start Date

Datatyp

date

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0808070
Administered Dose
Beskrivning

Dose

Datatyp

float

Måttenheter
  • mg
Alias
UMLS CUI [1]
C0178602
mg
Stop Date
Beskrivning

Study Drug Administration Stop Date

Datatyp

date

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0806020
Dose Modification
Beskrivning

Record toxicities on the Adverse Events page.

Datatyp

integer

Alias
UMLS CUI [1,1]
C1707811
UMLS CUI [1,2]
C0392360
If other, specify:
Beskrivning

Other Dose Modification Reason

Datatyp

text

Alias
UMLS CUI [1,1]
C1707811
UMLS CUI [1,2]
C3840932
Missed Doses
Beskrivning

Record the number of missed doses, if any, for the time between the start and stop dates.

Datatyp

integer

Alias
UMLS CUI [1,1]
C1709043
UMLS CUI [1,2]
C0750480
Tillbaka till toppen

Similar models

Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Study Drug Administration
Study Drug Administration Start Date
Item
Start Date
date
C0013227 (UMLS CUI [1,1])
C0808070 (UMLS CUI [1,2])
Dose
Item
Administered Dose
float
C0178602 (UMLS CUI [1])
Study Drug Administration Stop Date
Item
Stop Date
date
C0013227 (UMLS CUI [1,1])
C0806020 (UMLS CUI [1,2])
Item
Dose Modification
integer
C1707811 (UMLS CUI [1,1])
C0392360 (UMLS CUI [1,2])
Study Drug Dose Modification
Code List
Dose Modification
CL Item
Drug-related Toxicity (AE) (1)
CL Item
Nondrug-related Toxicity (AE) (2)
CL Item
Patient Request  (3)
CL Item
Toxicity lmproved  (4)
CL Item
No Modification (5)
CL Item
Other (specify) (6)
Other Dose Modification Reason
Item
If other, specify:
text
C1707811 (UMLS CUI [1,1])
C3840932 (UMLS CUI [1,2])
Missed Doses
Item
Missed Doses
integer
C1709043 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial